Clinical follow-up of patients with implantable cardioverter-defibrillator
- PMID: 17364112
- DOI: 10.1590/s0066-782x2007000100002
Clinical follow-up of patients with implantable cardioverter-defibrillator
Abstract
Objective: To report appropriate (AT) and inappropriate (IT) ICD therapies in patients with ischemic and nonischemic heart disease, as well as early and late procedure-related complications.
Methods: One hundred and fifty-five patients (119 male and 36 female), mean age 47 years (21-88), who underwent ICD implantation between 1994 and March 2003 were analyzed. Patients were divided into the following groups: Group I--Post-AMI patients (n = 80); Group II--Patients with nonischemic heart disease and LV ejection fraction < 40% (n = 45), Chagas disease (n = 18), idiopathic dilated cardiomyopathy (n= 12), hypertensive disease (n = 8), hypertrophic cardiomyopathy (n = 4) and valvular heart disease (n = 3); Group III--Patients with arrhythmogenic right ventricular dysplasia (n = 13); and Group IV--Patients with channelopathies: Brugada Syndrome (n = 8) and idiopathic ventricular arrhythmias (n = 9). All patients underwent electrophysiological study (EPS) with induction of sustained ventricular arrhythmia ICD implantation.
Results: During the 26-month mean follow up, a high rate of appropriate ICD therapies (antitachycardia pacing and/or shock) was observed (46%) in the four groups, with no statistically significant difference. The four groups did not differ in either overall (8.4%) or arrhythmic mortality (1.3%). There was no correlation between appropriate ICD therapies and initial clinical presentation or inducible ventricular arrhythmia at EPS, and a 4% incidence of early and late procedure-related complications was found.
Conclusion: The high incidence of appropriate ICD therapy and low rate of sudden death in the patients studied suggest that ICD is a valuable strategy in the management of ischemic and nonischemic patients previously selected by means of EPS.
Similar articles
-
Long-term clinical outcome in patients with severe left ventricular dysfunction and an implantable cardioverter-defibrillator after ventricular tachyarrhythmias.Rev Port Cardiol. 2005 Apr;24(4):487-98. Rev Port Cardiol. 2005. PMID: 15977773 English, Portuguese.
-
Primary prevention of sudden cardiac death in a nonischemic dilated cardiomyopathy population: reappraisal of the role of programmed ventricular stimulation.Circ Arrhythm Electrophysiol. 2013 Jun;6(3):504-12. doi: 10.1161/CIRCEP.113.000216. Epub 2013 Apr 15. Circ Arrhythm Electrophysiol. 2013. PMID: 23588627
-
Impact of the presence and amount of myocardial fibrosis by cardiac magnetic resonance on arrhythmic outcome and sudden cardiac death in nonischemic dilated cardiomyopathy.Heart Rhythm. 2014 May;11(5):856-63. doi: 10.1016/j.hrthm.2014.01.014. Epub 2014 Jan 15. Heart Rhythm. 2014. PMID: 24440822
-
Implantable cardioverter defibrillators in arrhythmogenic right ventricular dysplasia/cardiomyopathy: patient outcomes, incidence of appropriate and inappropriate interventions, and complications.Circ Arrhythm Electrophysiol. 2013 Jun;6(3):562-8. doi: 10.1161/CIRCEP.113.000392. Epub 2013 May 14. Circ Arrhythm Electrophysiol. 2013. PMID: 23673907 Review.
-
Systematic review for the 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.Heart Rhythm. 2018 Oct;15(10):e253-e274. doi: 10.1016/j.hrthm.2017.10.037. Epub 2017 Nov 4. Heart Rhythm. 2018. PMID: 29097318
Cited by
-
Clinical Course After Cardioverter-Defibrillator Implantation: Chagasic Versus Ischemic Patients.Arq Bras Cardiol. 2016 Aug;107(2):99-100. doi: 10.5935/abc.20160101. Epub 2016 Jul 11. Arq Bras Cardiol. 2016. PMID: 27411097 Free PMC article.
-
Brugada Syndrome: The Role of Risk Stratification in Selecting Patients for Implantable Cardioverter-defibrillator Placement.Cureus. 2018 Jun 13;10(6):e2799. doi: 10.7759/cureus.2799. Cureus. 2018. PMID: 30116678 Free PMC article. Review.
-
Efficacy and Complications of Subcutaneous versus Conventional Cardioverter Defibrillators: A Systematic Review and Meta-analysis.Curr Cardiol Rev. 2022;18(3):e081221198647. doi: 10.2174/1573403X17666211208100151. Curr Cardiol Rev. 2022. PMID: 34879809 Free PMC article.
-
SBC Guideline on the Diagnosis and Treatment of Patients with Cardiomyopathy of Chagas Disease - 2023.Arq Bras Cardiol. 2023 Jun 26;120(6):e20230269. doi: 10.36660/abc.20230269. Arq Bras Cardiol. 2023. PMID: 37377258 Free PMC article. English, Portuguese. No abstract available.
-
Mortality risk in chronic Chagas cardiomyopathy: a systematic review and meta-analysis.ESC Heart Fail. 2021 Dec;8(6):5466-5481. doi: 10.1002/ehf2.13648. Epub 2021 Oct 30. ESC Heart Fail. 2021. PMID: 34716744 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical